Tofacitinib Induced Long-term Clinical, Endoscopic, and Histological Remission as a 6th Line Agent in Medically Refractory Ulcerative Colitis

Inflamm Bowel Dis. 2021 Feb 16;27(3):e35-e36. doi: 10.1093/ibd/izaa296.

Authors

Rocio Sedano¹, Vipul Jairath²

Affiliations

¹ Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
² Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.

PMID: 33200783
DOI: 10.1093/ibd/izaa296

No abstract available

Keywords: biologics; inflammatory bowel disease; ulcerative colitis.

Publication types

Case Reports
Letter

MeSH terms

Colitis, Ulcerative* / drug therapy
Humans
Piperidines / therapeutic use*
Pyrimidines / therapeutic use*
Remission Induction

Substances

Piperidines
Pyrimidines
tofacitinib